Sector
Biopharma CDMO
WatchKorean contract development and manufacturing for biologics: Samsung Biologics, Celltrion, Lotte Biologics, SK pharmteco, and the Songdo cluster around them.
Standing view
The desk's standing view: Korea is the second pole of global biologics manufacturing capacity after the United States, and European pharma is its anchor customer base. The sector's competitive advantage is scale and delivery reliability, not price.
Contracts with Korean CDMOs are negotiated on a timeline logic. The desk's negotiation coverage sits here.
On the desk
Nothing published on Biopharma CDMO yet. Sign in and watch it to be told when there is.